These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
293 related articles for article (PubMed ID: 19757823)
1. Aminoimidazoles as potent and selective human beta-secretase (BACE1) inhibitors. Malamas MS; Erdei J; Gunawan I; Barnes K; Johnson M; Hui Y; Turner J; Hu Y; Wagner E; Fan K; Olland A; Bard J; Robichaud AJ J Med Chem; 2009 Oct; 52(20):6314-23. PubMed ID: 19757823 [TBL] [Abstract][Full Text] [Related]
2. Design and synthesis of 5,5'-disubstituted aminohydantoins as potent and selective human beta-secretase (BACE1) inhibitors. Malamas MS; Erdei J; Gunawan I; Turner J; Hu Y; Wagner E; Fan K; Chopra R; Olland A; Bard J; Jacobsen S; Magolda RL; Pangalos M; Robichaud AJ J Med Chem; 2010 Feb; 53(3):1146-58. PubMed ID: 19968289 [TBL] [Abstract][Full Text] [Related]
3. Di-substituted pyridinyl aminohydantoins as potent and highly selective human beta-secretase (BACE1) inhibitors. Malamas MS; Barnes K; Johnson M; Hui Y; Zhou P; Turner J; Hu Y; Wagner E; Fan K; Chopra R; Olland A; Bard J; Pangalos M; Reinhart P; Robichaud AJ Bioorg Med Chem; 2010 Jan; 18(2):630-9. PubMed ID: 20045648 [TBL] [Abstract][Full Text] [Related]
4. Design, synthesis, and X-ray structure of potent memapsin 2 (beta-secretase) inhibitors with isophthalamide derivatives as the P2-P3-ligands. Ghosh AK; Kumaragurubaran N; Hong L; Kulkarni SS; Xu X; Chang W; Weerasena V; Turner R; Koelsch G; Bilcer G; Tang J J Med Chem; 2007 May; 50(10):2399-407. PubMed ID: 17432843 [TBL] [Abstract][Full Text] [Related]
5. Design, synthesis, and qualitative structure-activity evaluations of novel β-secretase inhibitors as potential Alzheimer's drug leads. Al-Tel TH; Semreen MH; Al-Qawasmeh RA; Schmidt MF; El-Awadi R; Ardah M; Zaarour R; Rao SN; El-Agnaf O J Med Chem; 2011 Dec; 54(24):8373-85. PubMed ID: 22044119 [TBL] [Abstract][Full Text] [Related]
6. New pyrazolyl and thienyl aminohydantoins as potent BACE1 inhibitors: exploring the S2' region. Malamas MS; Erdei J; Gunawan I; Barnes K; Hui Y; Johnson M; Robichaud A; Zhou P; Yan Y; Solvibile W; Turner J; Fan KY; Chopra R; Bard J; Pangalos MN Bioorg Med Chem Lett; 2011 Sep; 21(18):5164-70. PubMed ID: 21835615 [TBL] [Abstract][Full Text] [Related]
7. Macrocyclic peptidomimetic beta-secretase (BACE-1) inhibitors with activity in vivo. Machauer R; Laumen K; Veenstra S; Rondeau JM; Tintelnot-Blomley M; Betschart C; Jaton AL; Desrayaud S; Staufenbiel M; Rabe S; Paganetti P; Neumann U Bioorg Med Chem Lett; 2009 Mar; 19(5):1366-70. PubMed ID: 19195887 [TBL] [Abstract][Full Text] [Related]
8. From fragment screening to in vivo efficacy: optimization of a series of 2-aminoquinolines as potent inhibitors of beta-site amyloid precursor protein cleaving enzyme 1 (BACE1). Cheng Y; Judd TC; Bartberger MD; Brown J; Chen K; Fremeau RT; Hickman D; Hitchcock SA; Jordan B; Li V; Lopez P; Louie SW; Luo Y; Michelsen K; Nixey T; Powers TS; Rattan C; Sickmier EA; St Jean DJ; Wahl RC; Wen PH; Wood S J Med Chem; 2011 Aug; 54(16):5836-57. PubMed ID: 21707077 [TBL] [Abstract][Full Text] [Related]
9. Structure-based design and synthesis of macrocyclic peptidomimetic beta-secretase (BACE-1) inhibitors. Machauer R; Veenstra S; Rondeau JM; Tintelnot-Blomley M; Betschart C; Neumann U; Paganetti P Bioorg Med Chem Lett; 2009 Mar; 19(5):1361-5. PubMed ID: 19195886 [TBL] [Abstract][Full Text] [Related]
10. P-glycoprotein efflux and other factors limit brain amyloid beta reduction by beta-site amyloid precursor protein-cleaving enzyme 1 inhibitors in mice. Meredith JE; Thompson LA; Toyn JH; Marcin L; Barten DM; Marcinkeviciene J; Kopcho L; Kim Y; Lin A; Guss V; Burton C; Iben L; Polson C; Cantone J; Ford M; Drexler D; Fiedler T; Lentz KA; Grace JE; Kolb J; Corsa J; Pierdomenico M; Jones K; Olson RE; Macor JE; Albright CF J Pharmacol Exp Ther; 2008 Aug; 326(2):502-13. PubMed ID: 18499745 [TBL] [Abstract][Full Text] [Related]
12. Discovery of cyclic sulfone hydroxyethylamines as potent and selective β-site APP-cleaving enzyme 1 (BACE1) inhibitors: structure-based design and in vivo reduction of amyloid β-peptides. Rueeger H; Lueoend R; Rogel O; Rondeau JM; Möbitz H; Machauer R; Jacobson L; Staufenbiel M; Desrayaud S; Neumann U J Med Chem; 2012 Apr; 55(7):3364-86. PubMed ID: 22380629 [TBL] [Abstract][Full Text] [Related]
13. Design and synthesis of aminohydantoins as potent and selective human β-secretase (BACE1) inhibitors with enhanced brain permeability. Malamas MS; Robichaud A; Erdei J; Quagliato D; Solvibile W; Zhou P; Morris K; Turner J; Wagner E; Fan K; Olland A; Jacobsen S; Reinhart P; Riddell D; Pangalos M Bioorg Med Chem Lett; 2010 Nov; 20(22):6597-605. PubMed ID: 20880704 [TBL] [Abstract][Full Text] [Related]
14. 2-Amino-3,4-dihydroquinazolines as inhibitors of BACE-1 (beta-site APP cleaving enzyme): Use of structure based design to convert a micromolar hit into a nanomolar lead. Baxter EW; Conway KA; Kennis L; Bischoff F; Mercken MH; Winter HL; Reynolds CH; Tounge BA; Luo C; Scott MK; Huang Y; Braeken M; Pieters SM; Berthelot DJ; Masure S; Bruinzeel WD; Jordan AD; Parker MH; Boyd RE; Qu J; Alexander RS; Brenneman DE; Reitz AB J Med Chem; 2007 Sep; 50(18):4261-4. PubMed ID: 17685503 [TBL] [Abstract][Full Text] [Related]
15. Fragment-based discovery of BACE1 inhibitors using functional assays. Godemann R; Madden J; Krämer J; Smith M; Fritz U; Hesterkamp T; Barker J; Höppner S; Hallett D; Cesura A; Ebneth A; Kemp J Biochemistry; 2009 Nov; 48(45):10743-51. PubMed ID: 19799414 [TBL] [Abstract][Full Text] [Related]
16. Tetrapeptides, as small-sized peptidic inhibitors; synthesis and their inhibitory activity against BACE1. Kakizawa T; Hidaka K; Hamada D; Yamaguchi R; Uemura T; Kitamura H; Tagad HD; Hamada T; Ziora Z; Hamada Y; Kimura T; Kiso Y J Pept Sci; 2010 Jun; 16(6):257-62. PubMed ID: 20474036 [TBL] [Abstract][Full Text] [Related]
17. Differential effects of gamma-secretase and BACE1 inhibition on brain Abeta levels in vitro and in vivo. Elvang AB; Volbracht C; Pedersen LØ; Jensen KG; Karlsson JJ; Larsen SA; Mørk A; Stensbøl TB; Bastlund JF J Neurochem; 2009 Sep; 110(5):1377-87. PubMed ID: 19519664 [TBL] [Abstract][Full Text] [Related]
18. The selective BACE1 inhibitor VIa reduces amyloid-β production in cell and mouse models of Alzheimer's disease. Cheng X; Zhou Y; Gu W; Wu J; Nie A; Cheng J; Zhou J; Zhou W; Zhang Y J Alzheimers Dis; 2013; 37(4):823-34. PubMed ID: 23948917 [TBL] [Abstract][Full Text] [Related]
19. Structure-based design of potent and selective cell-permeable inhibitors of human beta-secretase (BACE-1). Stachel SJ; Coburn CA; Steele TG; Jones KG; Loutzenhiser EF; Gregro AR; Rajapakse HA; Lai MT; Crouthamel MC; Xu M; Tugusheva K; Lineberger JE; Pietrak BL; Espeseth AS; Shi XP; Chen-Dodson E; Holloway MK; Munshi S; Simon AJ; Kuo L; Vacca JP J Med Chem; 2004 Dec; 47(26):6447-50. PubMed ID: 15588077 [TBL] [Abstract][Full Text] [Related]
20. In vivo beta-secretase 1 inhibition leads to brain Abeta lowering and increased alpha-secretase processing of amyloid precursor protein without effect on neuregulin-1. Sankaranarayanan S; Price EA; Wu G; Crouthamel MC; Shi XP; Tugusheva K; Tyler KX; Kahana J; Ellis J; Jin L; Steele T; Stachel S; Coburn C; Simon AJ J Pharmacol Exp Ther; 2008 Mar; 324(3):957-69. PubMed ID: 18156464 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]